[1]

Gu D, Dong N, Zheng Z, Lin D, Huang M, et al. 2018. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. The Lancet Infectious Diseases 18:37−46

doi: 10.1016/S1473-3099(17)30489-9
[2]

Hu F, Pan Y, Li H, Han R, Liu X, et al. 2024. Carbapenem-resistant Klebsiella pneumoniae capsular types, antibiotic resistance and virulence factors in China: a longitudinal, multi-centre study. Nature Microbiology 9:814−829

doi: 10.1038/s41564-024-01612-1
[3]

Xu Q, Xie M, Liu X, Heng H, Wang H, et al. 2023. Molecular mechanisms underlying the high mortality of hypervirulent Klebsiella pneumoniae and its effective therapy development. Signal Transduction and Targeted Therapy 8:221

doi: 10.1038/s41392-023-01490-9
[4]

Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, et al. 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 399:629−655

doi: 10.1016/S0140-6736(21)02724-0
[5]

Yang X, Sun Q, Li J, Jiang Y, Li Y, et al. 2022. Molecular epidemiology of carbapenem-resistant hypervirulent Klebsiella pneumoniae in China. Emerging Microbes & Infections 11:841−849

doi: 10.1080/22221751.2022.2049458
[6]

Pu D, Zhao J, Chang K, Zhuo X, Cao B. 2023. 'Superbugs' with hypervirulence and carbapenem resistance in Klebsiella pneumoniae: the rise of such emerging nosocomial pathogens in China. Science Bulletin 68:2658−2670

doi: 10.1016/j.scib.2023.09.040
[7]

Rahman NM, Maskell NA, West A, Teoh R, Arnold A, et al. 2011. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. New England Journal of Medicine 365:518−526

doi: 10.1056/NEJMoa1012740
[8]

Wyres KL, Lam MMC, Holt KE. 2020. Population genomics of Klebsiella pneumoniae. Nature Reviews Microbiology 18:344−359

doi: 10.1038/s41579-019-0315-1
[9]

Zumla A, Rao M, Wallis RS, Kaufmann SHE, Rustomjee R, et al. 2016. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. The Lancet Infectious Diseases 16:e47−e63

doi: 10.1016/S1473-3099(16)00078-5
[10]

Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. 2018. Host-directed therapies for bacterial and viral infections. Nature Reviews Drug Discovery 17:35−56

doi: 10.1038/nrd.2017.162
[11]

Ferreiro L, Toubes ME, Suárez-Antelo J, Rodríguez-Núñez N, Valdés L. 2024. Clinical overview of the physiology and pathophysiology of pleural fluid movement: a narrative review. ERJ Open Research 10:00050-2024

doi: 10.1183/23120541.00050-2024
[12]

Wong Fok Lung T, Charytonowicz D, Beaumont KG, Shah SS, Sridhar SH, et al. 2022. Klebsiella pneumoniae induces host metabolic stress that promotes tolerance to pulmonary infection. Cell Metabolism 34:761−774.e769

doi: 10.1016/j.cmet.2022.03.009
[13]

Hsueh PC, Wu KA, Yang CY, Hsu CW, Wang CL, et al. 2020. Metabolomic profiling of parapneumonic effusion reveals a regulatory role of dipeptides in interleukin-8 production in neutrophil-like cells. Analytica Chimica Acta 1128:238−250

doi: 10.1016/j.aca.2020.06.022
[14]

Dumigan A, Cappa O, Morris B, Sá Pessoa J, Calderon-Gonzalez R, et al. 2022. In vivo single-cell transcriptomics reveal Klebsiella pneumoniae skews lung macrophages to promote infection. EMBO Molecular Medicine 14:e16888

doi: 10.15252/emmm.202216888
[15]

Zhai Y, Liu L, Zhang F, Chen X, Wang H, et al. 2025. Network pharmacology: a crucial approach in traditional Chinese medicine research. Chinese Medicine 20:8

doi: 10.1186/s13020-024-01056-z
[16]

Li S, Zhang B. 2013. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chinese Journal of Natural Medicines 11:110−120

doi: 10.1016/S1875-5364(13)60037-0
[17]

Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, et al. 2022. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends in Pharmacological Sciences 43:136−150

doi: 10.1016/j.tips.2021.11.004
[18]

Wang Y, Wang Y, Cai N, Xu T, He F. 2021. Anti-inflammatory effects of curcumin in acute lung injury: in vivo and in vitro experimental model studies. International Immunopharmacology 96:107600

doi: 10.1016/j.intimp.2021.107600
[19]

Russo TA, Marr CM. 2019. Hypervirulent Klebsiella pneumoniae. Clinical Microbiology Reviews 32:e00001-19

doi: 10.1128/CMR.00001-19
[20]

Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, et al. 2021. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Research 49:W388−W396

doi: 10.1093/nar/gkab382
[21]

Osorio D, Zhong Y, Li G, Xu Q, Yang Y, et al. 2022. scTenifoldKnk: an efficient virtual knockout tool for gene function predictions via single-cell gene regulatory network perturbation. Patterns 3:100434

doi: 10.1016/j.patter.2022.100434
[22]

Yang Y, Li G, Zhong Y, Xu Q, Chen BJ, et al. 2023. Gene knockout inference with variational graph autoencoder learning single-cell gene regulatory networks. Nucleic Acids Research 51:6578−6592

doi: 10.1093/nar/gkad450
[23]

Gao K, Liu L, Lei S, Li Z, Huo P, et al. 2025. HERB 2.0: an updated database integrating clinical and experimental evidence for traditional Chinese medicine. Nucleic Acids Research 53:D1404−D1414

doi: 10.1093/nar/gkae1037
[24]

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Research 13:2498−2504

doi: 10.1101/gr.1239303
[25]

Liu Y, Yang X, Gan J, Chen S, Xiao ZX, et al. 2022. CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Research 50:W159−W164

doi: 10.1093/nar/gkac394
[26]

Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, et al. 2010. CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. Journal of Computational Chemistry 31:671−690

doi: 10.1002/jcc.21367
[27]

Best RB, Zhu X, Shim J, Lopes PEM, Mittal J, et al. 2012. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone ϕ, ψ and side-chain χ1 and χ2 dihedral angles. Journal of Chemical Theory and Computation 8:3257−3273

doi: 10.1021/ct300400x
[28]

Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, et al. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proceedings of the National Academy of Sciences of the United States of America 98:13681−13686

doi: 10.1073/pnas.251194298
[29]

Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, et al. 2008. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13:311−320

doi: 10.1016/j.ccr.2008.02.009
[30]

Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, et al. 2013. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341:84−87

doi: 10.1126/science.1233606
[31]

Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundbäck T, et al. 2014. The cellular thermal shift assay for evaluating drug target interactions in cells. Nature Protocols 9:2100−2122

doi: 10.1038/nprot.2014.138
[32]

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, et al. 2015. Robust enumeration of cell subsets from tissue expression profiles. Nature Methods 12:453−457

doi: 10.1038/nmeth.3337
[33]

Liao M, Liu Y, Yuan J, Wen Y, Xu G, et al. 2020. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nature Medicine 26:842−844

doi: 10.1038/s41591-020-0901-9
[34]

Delorey TM, Ziegler CGK, Heimberg G, Normand R, Yang Y, et al. 2021. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature 595:107−113

doi: 10.1038/s41586-021-03570-8
[35]

Finley D, Bartel B, Varshavsky A. 1989. The tails of ubiquitin precursors are ribosomal proteins whose fusion to ubiquitin facilitates ribosome biogenesis. Nature 338:394−401

doi: 10.1038/338394a0
[36]

Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. 2010. The emerging mechanisms of isoform-specific PI3K signalling. Nature Reviews Molecular Cell Biology 11:329−341

doi: 10.1038/nrm2882
[37]

Genheden S, Ryde U. 2015. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery 10:449−461

doi: 10.1517/17460441.2015.1032936
[38]

Xue C, Yao Q, Gu X, Shi Q, Yuan X, et al. 2023. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduction and Targeted Therapy 8:310

doi: 10.1038/s41392-023-01468-7
[39]

Choby JE, Howard-Anderson J, Weiss DS. 2020. Hypervirulent Klebsiella pneumoniae − clinical and molecular perspectives. Journal of Internal Medicine 287:283−300

doi: 10.1111/joim.13007
[40]

Mu A, Klare WP, Baines SL, Ignatius Pang CN, Guérillot R, et al. 2023. Integrative omics identifies conserved and pathogen-specific responses of sepsis-causing bacteria. Nature Communications 14:1530

doi: 10.1038/s41467-023-37200-w
[41]

Vandereyken K, Sifrim A, Thienpont B, Voet T. 2023. Methods and applications for single-cell and spatial multi-omics. Nature Reviews Genetics 24:494−515

doi: 10.1038/s41576-023-00580-2
[42]

Baysoy A, Bai Z, Satija R, Fan R. 2023. The technological landscape and applications of single-cell multi-omics. Nature Reviews Molecular Cell Biology 24:695−713

doi: 10.1038/s41580-023-00615-w
[43]

Singh P, Gollapalli K, Mangiola S, Schranner D, Yusuf MA, et al. 2023. Taurine deficiency as a driver of aging. Science 380:eabn9257

doi: 10.1126/science.abn9257
[44]

Ye H, Borusak S, Eberl C, Krasenbrink J, Weiss AS, et al. 2023. Ecophysiology and interactions of a taurine-respiring bacterium in the mouse gut. Nature Communications 14:5533

doi: 10.1038/s41467-023-41008-z
[45]

Xiao Z, Jiang S, Fu S, Zhang X, Qi X, et al. 2025. Unveiling the therapeutic mechanism of Epimedium herba on prostate cancer through network pharmacology and experimental validation. Chinese Journal of Natural Medicines 23:100016

doi: 10.1016/j.cjnm.2025.100016
[46]

Racz LZ, Racz CP, Pop LC, Tomoaia G, Mocanu A, et al. 2022. Strategies for improving bioavailability, bioactivity, and physical-chemical behavior of curcumin. Molecules 27:6854

doi: 10.3390/molecules27206854
[47]

Suresh MV, Francis S, Aktay S, Kralovich G, Raghavendran K. 2023. Therapeutic potential of curcumin in ARDS and COVID-19. Clinical and Experimental Pharmacology and Physiology 50:267−276

doi: 10.1111/1440-1681.13744
[48]

Jiang L, Guo P, Ju J, Zhu X, Wu S, et al. 2023. Inhalation of L-arginine-modified liposomes targeting M1 macrophages to enhance curcumin therapeutic efficacy in ALI. European Journal of Pharmaceutics and Biopharmaceutics 182:21−31

doi: 10.1016/j.ejpb.2022.11.017
[49]

Peng T, Rao J, Zhang T, Wang Y, Li N, et al. 2023. Elucidation of the relationship between evodiamine-induced liver injury and CYP3A4-mediated metabolic activation by UPLC-MS/MS analysis. Analytical and Bioanalytical Chemistry 415:5619−5635

doi: 10.1007/s00216-023-04831-3
[50]

Lin L, Liu Y, Tang R, Ding S, Lin H, et al. 2024. Evodiamine: an extremely potential drug development candidate of alkaloids from Evodia rutaecarpa. International Journal of Nanomedicine 19:9843−9870

doi: 10.2147/IJN.S459510
[51]

Tadtong S, Atiwanitchakul K, Moohammad M, Chittasupho C, Tangjidapichai C, et al. 2026. Combined anti-inflammatory effects of curcumin and evodiamine: in vitro synergy, docking, and molecular orbital insights. International Journal of Molecular Sciences 27:3834

doi: 10.3390/ijms27093834